ScholarMate
English简体中文繁體中文
客服热线:400-1616-289
登录注册
期刊论文

Efficacy and safety of apatinib in patients with untreated or chemotherapy-refractory soft tissue sarcoma: a multicenter, phase 2 trial

Yu, Wenxi; Zhang, Hongmei; Chen, Jing; Zhang, Xing; Chen, Yong; Qu, Guofan; Huang, Gang; Zhou, Yuhong; Ye, Ting; Fan, Zhengfu*; Yao, Yang*复旦大学; 华中科技大学; 上海交通大学; 哈尔滨医科大学; 中国人民解放军第四军医大学; 中山大学; 6; y
Annals of Translational Medicine2022-9DOI: 10.21037/atm-22-4229
4被引10阅读
引用收藏
分享

摘要

Background: Anti-angiogenic agents have been reported to exert promising clinical activity for advanced soft tissue sarcoma (STS). Apatinib, a vascular endothelial growth factor receptor-2 tyrosine kinase inhibitor, is effective and safe for various solid tumors, but its role in STS remains unclear. The aim of this study was to explore the efficacy and safety of apatinib in patients with untreated or chemotherapy-refractory STS. @@@ Methods: In this multicenter, single-arm, phase 2 trial, patients aged 18-70 years with untreated or chemotherapy-refractory STS were enrolled and received 500 mg apatinib per day. During treatment, patients were followed up with imaging every 8 weeks. The primary endpoint was the 6-month progression-free survival (PFS) rate. The secondary endpoints were objective response rate (ORR), overall survival (OS), and adverse events (AEs), which were graded following the National Cancer Institute common terminology criteria for AEs version 4.03. @@@ Results: From June 2017 to October 2018, 53 patients were enrolled, 51 of whom received at least one dose of apatinib. Of the 53 patients, 41 (77.4%) had chemotherapy-refractory disease. The median follow-up was 13.3 months. The 6- and 12-month PFS rates were 46.8% and 25.2%, respectively, with a median PFS of 5.6 months [95% confidence interval (CI): 3.8-9.2 months]. The median PFS was 5.5 months for chemotherapy-refractory patients, 9.1 months for untreated patients, 13.9 months for patients with alveolar soft part sarcoma (ASPS), and 3.7 months for patients with clear cell sarcoma (CCS). The 12- and 24-month OS rates were 58.6% and 44.9%, respectively, with a median OS of 20.0 months (95% CI: 9.2-31.1 months). The median OS was 10.7 months for chemotherapy-refractory patients and not estimated for untreated, ASPS, nor CCS patients. In 50 evaluable patients, the ORR was 18.0% and the disease control rate was 86.0%. These results were similar to those of the per-protocol set. The most common grade 3 or 4 AEs included hypertension [30 (58.8%) of 51 patients], leukopenia [12 (23.5%)], proteinuria [8 (15.69%)], and hematuria [8 (15.69%)]. One patient died of unknown cause. @@@ Conclusions: This study suggested that apatinib might be effective and tolerable in patients with untreated or chemotherapy-refractory STS (NCT03064243).

学科与关键词

关键词
Soft tissue sarcoma (STS)neoplasm drug resistanceapatinibangiogenesis
相关
加载中…
  • Anlotinib as a maintenance treatment for advanced soft tissue sarcoma after first-line chemotherapy (ALTER-S006) a multicentre, open-label, single-arm, phase 2 trial
    Xu, Bushu; Pan, Qiuzhong; Pan, Hua; Li, Haomiao; Li, Xianan; Chen, Jing; Pang, Danmei; Zhang, Baoqing; Weng, Desheng; Peng, Ruiqing; Fang, Meiyu*; Zhang, Xing*ECLINICALMEDICINE, 2023, 64: 102240.被引 1
  • Safety and efficacy of apatinib in patients with advanced gastric or gastroesophageal junction adenocarcinoma after the failure of two or more lines of chemotherapy (AHEAD): a prospective, single-arm, multicenter, phase IV study
    Li, Jin; Qin, Shukui*; Wen, Lu; Wang, Junsheng; Deng, Wenying; Guo, Weijian; Jia, Tongfu; Jiang, Da; Zhang, Guifang; He, Yifu; Ba, Yi; Zhong, Haijun; Wang, Lin; Lin, Xiaoyan; Yang, Jianwei; Zhao, Jun; Bai, Yuxian; Wu, Xiangyuan; Gao, Feng; Sun, Guogui; Wu, Yongjuan; Ye, Feng; Wang, Qiong; Xie, Zhong; Yi, Tienan; Huang, Yong; Yu, Guohua; Lu, Lin; Yuan, Ying; Li, Wei; Liu, Likun; Sun, Yuping; Sun, Ying; Yin, Lifeng; Hou, ZhiguoBMC Medicine, 2023, 21(1): 173.被引 1
  • Multiple-dose up-titration study to evaluate the pharmacokinetics, safety and antitumor activity of apatinib in advanced gastric adenocarcinoma
    Wang, Yonggang; Wang, Chang; Zhang, Yanqiao; Hao, Jiqing; Yang, Nong; Wang, Jvfeng; Peng, Min; Liu, Tianshu; Zhang, Guifang; Zhan, Xianbao; Zeng, Shan; Zhang, Yifan; Gao, Yong*; Yao, Yang*Frontiers in Oncology, 2022, 12: 876899.被引 1
查看全部 →

发表信息

论文状态
公开发表
期刊
Annals of Translational Medicine
发表日期
2022-09
卷期
第 10 卷, 第 18 期
页码
981
DOI
10.21037/atm-22-4229
期刊等级
4区
成果收录
SCIE
资助标注
Shanghai Science and Technology Committee [17411950300, 1741195030X]; Jiangsu Hengrui Pharmaceuticals Co., Ltd.

作者

  • Y

    Yu, Wenxi (第一作者)

    6 · shanghai jiao tong univ

  • Z

    Zhang, Hongmei

    fourth mil med univ

查看全部 11 位作者收起作者
  • C

    Chen, Jing

    huazhong univ sci & technol

  • Z

    Zhang, Xing

    sun yat sen univ

  • C

    Chen, Yong

    fudan univ

  • Q

    Qu, Guofan

    harbin med univ

  • H

    Huang, Gang

    hunan prov tumor hosp

  • Z

    Zhou, Yuhong

    fudan univ

  • Y

    Ye, Ting

    huazhong univ sci & technol

  • F

    Fan, Zhengfu (通讯)

  • Y

    Yao, Yang (通讯)

    6 · shanghai jiao tong univ

登录解锁更多功能

  • 收藏这篇,随时在“我的 · 收藏”找回
  • 认领你的成果,生成推广素材
  • 关注作者获取最新成果
  • 加入项目组、协同写作
注册 / 登录

产品服务

  • 科研之友
  • 创新城
  • 科创云

服务支持

  • 帮助中心
  • 隐私政策
  • 服务条款

联系方式

在线客服:【】
客服热线:400-1616-289
电子邮箱:support@scholarmate.com

关注或下载科研之友

微信二维码
微信公众号
客户端下载二维码
下载客户端
科研成果科研人员科研机构科研动态爱瑞思软件

©2026 深圳市科研之友网络服务有限公司

公安备案图标粤公网安备 44030502000213
粤ICP备 16046710 号粤B2-20110417